Keyphrases
Alzheimer's Disease
100%
Cerebrospinal Fluid Biomarkers
100%
Late-onset Alzheimer's Disease
100%
Neuronal Injury
100%
Neuroinflammation
33%
Clinical Trials
33%
Mild Cognitive Impairment
33%
Clinical Status
33%
Rate of Change
33%
Injury Levels
33%
Phospho-tau181
33%
Trial Enrollment
33%
Normal Cognition
33%
Cognitively Normal
33%
Alzheimer's Disease Neuroimaging Initiative
33%
Disease Stage
33%
SNAP-25
33%
Amyloid Positivity
33%
Secondary Prevention Trials
33%
Visinin-like protein-1
33%
Cerebrospinal Fluid Samples
33%
YKL-40
33%
Biomarker Changes
33%
Trial Design
33%
Clinical Group
33%
Disease Groups
33%
Generalized Linear Mixed Model
33%
Amyloid Status
33%
Targeted Population
33%
Injury Marker
33%
Synaptic Injury
33%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Alzheimer's Disease
100%
Amyloid Protein
80%
Clinical Trial
20%
Synapsin I
20%
Nervous System Inflammation
20%
Mild Cognitive Impairment
20%
Synaptosomal Associated Protein 25
20%
Mixed Model
20%
Visinin
20%
Diseases
20%
Biochemistry, Genetics and Molecular Biology
Liquid
100%
Amyloid Protein
100%
Clinical Trial
25%
Tau
25%
Synapsin I
25%
Neuroscience
Alzheimer's Disease
100%
Amyloid Protein
80%
Mild Cognitive Impairment
20%
Synapsin I
20%
Visinin
20%
Synaptosomal Associated Protein 25
20%